Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
NASDAQ:OTLK
OTLK Analyst Ratings
Moderate Buy
1 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
OTLK Stock 12 Month Forecast
Average Price Target
$5.50
▲(202.20% Upside)
| Highest Price Target$10.00 | Average Price Target$5.50 | Lowest Price Target$1.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Ascendiant
$10
Buy
449.45%
Upside
Reiterated
12/20/25
Outlook Therapeutics: Strengthened Case for ONS-5010 Drives Attractive Risk/Reward and Increased $10 Price TargetWe are adjusting our FY26 estimates for revenue to $14 million, from $25 million, and for EPS to $(0.99) from $(1.24). ONS-5010 development: Outlook has one main therapeutic candidate, ONS-5010 (named LYTENAVA) which is a proprietary ophthalmic formulation of bevacizumab (Avastin) product for the treatment of wet AMD and other eye diseases. Avastin is FDA approved and used widely in oncology indications but is also used off-label for the treatment of several ophthalmic diseases. Outlook is developing LYTENAVA as a replacement for the use of off-label Avastin in the treatment of wet AMD. FDA issued 1 st On August 30, 2023, Outlook announced that the FDA issued a Complete Response Letter (CRL) for the BLA for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD.
H.C. Wainwright
$1.47→$1
Hold
-45.05%
Downside
Reiterated
11/14/25
Guggenheim
Hold
―
Downgraded
08/28/25
Chardan Capital
$3
Hold
64.84%
Upside
Reiterated
08/28/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Ascendiant
$10
Buy
449.45%
Upside
Reiterated
12/20/25
Outlook Therapeutics: Strengthened Case for ONS-5010 Drives Attractive Risk/Reward and Increased $10 Price TargetWe are adjusting our FY26 estimates for revenue to $14 million, from $25 million, and for EPS to $(0.99) from $(1.24). ONS-5010 development: Outlook has one main therapeutic candidate, ONS-5010 (named LYTENAVA) which is a proprietary ophthalmic formulation of bevacizumab (Avastin) product for the treatment of wet AMD and other eye diseases. Avastin is FDA approved and used widely in oncology indications but is also used off-label for the treatment of several ophthalmic diseases. Outlook is developing LYTENAVA as a replacement for the use of off-label Avastin in the treatment of wet AMD. FDA issued 1 st On August 30, 2023, Outlook announced that the FDA issued a Complete Response Letter (CRL) for the BLA for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD.
H.C. Wainwright
$1.47→$1
Hold
-45.05%
Downside
Reiterated
11/14/25
Guggenheim
Hold
―
Downgraded
08/28/25
Chardan Capital
$3
Hold
64.84%
Upside
Reiterated
08/28/25
Best Analysts Covering Outlook Therapeutics
1 Month
xxx
Success Rate
2/9 ratings generated profit
Average Return
+1.54%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 22.22% of your transactions generating a profit, with an average return of +1.54% per trade.
3 Months
xxx
Success Rate
5/9 ratings generated profit
Average Return
+18.40%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +18.40% per trade.
1 Year
Success Rate
4/9 ratings generated profit
Average Return
-13.28%
reiterated a buy rating 9 days ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -13.28% per trade.
2 Years
xxx
Success Rate
2/9 ratings generated profit
Average Return
-44.90%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 22.22% of your transactions generating a profit, with an average return of -44.90% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
OTLK Analyst Recommendation Trends
Rating
Apr 25
May 25
Aug 25
Sep 25
Nov 25
Strong Buy
4
4
2
1
0
Buy
0
0
1
1
1
Hold
1
0
3
4
5
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
4
6
6
6
Each month's total comprises the sum of three months' worth of ratings.
OTLK Financial Forecast
OTLK Stock Forecast FAQ
What is OTLK’s average 12-month price target, according to analysts?
Based on analyst ratings, Outlook Therapeutics’s 12-month average price target is 5.50.
What is OTLK’s upside potential, based on the analysts’ average price target?
Outlook Therapeutics has 202.20% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is OTLK a Buy, Sell or Hold?
Outlook Therapeutics has a consensus rating of Moderate Buy which is based on 1 buy ratings, 1 hold ratings and 0 sell ratings.
What is Outlook Therapeutics’s price target?
The average price target for Outlook Therapeutics is 5.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $1.00. The average price target represents 202.20% Increase from the current price of $1.82.
The highest analyst price target is $10.00 ,the lowest forecast is $1.00. The average price target represents 202.20% Increase from the current price of $1.82.
What do analysts say about Outlook Therapeutics?
Outlook Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of OTLK?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.